New Data Supports Efficacy and Safety of Boehringer Ingelheim’s Cyltezo, a Humira Biosimilar

Interchangeability

Today, Boehringer Ingelheim announced new one-year data for their adalimumab biosimilar, Cyltezo®.  VOLTAIRE®-RA, a 48 week Phase III clinical trial, compared Cyltezo® (adalimumab-adbm) to Humira.  The results showed that Cyltezo® has equivalent efficacy, safety, and immunogenicity to Humira.  The data also showed consistent results when patients were switched to Cyltezo® from the reference product.  The data will be presented at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting on November 7, 2017 in San Diego, California.

Download PDF

Comments are closed.